Symbols / BNTC Stock $11.84 -1.99% Benitec Biopharma Inc.

Healthcare • Biotechnology • United States • NCM
BNTC (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index —
Sector Healthcare
Industry Biotechnology
CEO —
Exch · Country NCM · United States
Market Cap 405.58M
Enterprise Value —
Income —
Sales —
FCF (ttm) -4.36M
Book/sh —
Cash/sh —
Employees —
Insider 10d —
IPO —
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout —
P/E —
Forward P/E —
PEG —
P/S —
P/B —
P/C —
EV/EBITDA —
EV/Sales —
Quick Ratio —
Current Ratio —
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.08
EPS next Y —
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) —
Earnings (prior) —
ROA —
ROE —
ROIC —
Gross Margin —
Oper. Margin —
Profit Margin —
Shs Outstand 34.25M
Shs Float —
Insider Own —
Instit Own —
Short Float —
Short Ratio —
Short Interest —
52W High —
vs 52W High —
52W Low —
vs 52W Low —
Beta —
Impl. Vol. —
Rel Volume —
Avg Volume —
Volume —
Target (mean) $24.20
Tgt Median $24.00
Tgt Low $17.00
Tgt High $32.00
# Analysts —
Recom —
Prev Close $12.08
Price $11.84
Change -1.99%
About

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$24.20
Mean price target
2. Current target
$11.84
Latest analyst target
3. DCF / Fair value
$-2.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.84
Low
$17.00
High
$32.00
Mean
$24.20

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-05-12 init Evercore ISI Group — → Outperform $25
2026-03-09 reit HC Wainwright & Co. Buy → Buy $32
2025-11-24 main HC Wainwright & Co. Buy → Buy $32
2025-11-04 main HC Wainwright & Co. Buy → Buy $35
2025-11-04 main Citizens Market Outperform → Market Outperform $22
2025-09-24 reit JMP Securities Market Outperform → Market Outperform $20
2025-09-16 main Oppenheimer Outperform → Outperform $29
2025-05-19 reit HC Wainwright & Co. Buy → Buy $28
2025-05-15 reit JMP Securities Market Outperform → Market Outperform $20
2025-04-10 main JMP Securities Market Outperform → Market Outperform $20
2025-03-24 reit HC Wainwright & Co. Buy → Buy $28
2025-03-18 reit Citizens Capital Markets Market Outperform → Market Outperform $18
2025-02-21 reit HC Wainwright & Co. Buy → Buy $28
2024-12-13 init Baird — → Outperform $30
2024-12-03 reit Guggenheim Buy → Buy $17
2024-07-22 init Leerink Partners — → Outperform $13
2024-06-13 init Piper Sandler — → Overweight $30
2024-04-22 main JMP Securities Market Outperform → Market Outperform $16
2024-02-15 main JMP Securities Market Outperform → Market Outperform $10
2024-01-24 main JMP Securities Market Outperform → Market Outperform $8
News
RSS: Latest BNTC news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Revenue
0.00
0.00
-100.00%
0.07
+2.74%
0.07
Operating Revenue
0.00
0.00
-100.00%
0.07
+2.74%
0.07
Cost Of Revenue
—
—
0.00
-100.00%
0.01
Reconciled Cost Of Revenue
—
—
0.00
-100.00%
0.01
Gross Profit
—
—
0.07
+17.19%
0.06
Operating Expense
41.77
+85.70%
22.49
+17.40%
19.16
+6.91%
17.92
Research And Development
18.33
+17.45%
15.61
+22.19%
12.77
+13.33%
11.27
Selling General And Administration
23.43
+235.28%
6.99
+9.51%
6.38
-3.97%
6.65
General And Administrative Expense
23.43
+235.28%
6.99
+9.51%
6.38
-3.97%
6.65
Salaries And Wages
—
—
0.29
-52.53%
0.61
Other Gand A
23.43
+235.28%
6.99
+9.51%
6.38
-3.97%
6.65
Other Operating Expenses
—
-0.11
—
0.01
Total Expenses
41.77
+85.70%
22.49
+17.40%
19.16
+6.86%
17.93
Operating Income
-41.77
-85.70%
-22.49
-17.87%
-19.08
-6.87%
-17.85
Total Operating Income As Reported
-41.77
-85.70%
-22.49
-17.87%
-19.08
-6.87%
-17.85
EBITDA
-41.37
-86.79%
-22.15
-18.43%
-18.70
-5.15%
-17.78
Normalized EBITDA
-42.06
-89.59%
-22.19
-21.35%
-18.28
-4.22%
-17.54
Reconciled Depreciation
0.40
+15.45%
0.34
-9.97%
0.38
-2.81%
0.39
EBIT
-41.77
-85.70%
-22.49
-17.87%
-19.08
-4.98%
-18.18
Total Unusual Items
0.69
+1676.92%
0.04
+109.33%
-0.42
-72.02%
-0.24
Total Unusual Items Excluding Goodwill
0.69
+1676.92%
0.04
+109.33%
-0.42
-72.02%
-0.24
Special Income Charges
0.76
0.00
—
—
Other Special Charges
-0.76
—
—
—
Net Income
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Pretax Income
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Net Non Operating Interest Income Expense
3.29
+263.50%
0.90
+2839.39%
-0.03
-3.13%
-0.03
Interest Expense Non Operating
—
—
0.03
+3.13%
0.03
Net Interest Income
3.29
+263.50%
0.90
+2839.39%
-0.03
-3.13%
-0.03
Interest Expense
—
—
0.03
+3.13%
0.03
Interest Income Non Operating
—
—
—
—
Interest Income
—
—
—
—
Other Income Expense
0.56
+440.61%
-0.17
+63.17%
-0.45
-39.13%
-0.32
Other Non Operating Income Expenses
-0.13
+35.78%
-0.20
-580.00%
-0.03
+62.03%
-0.08
Gain On Sale Of Security
-0.07
-282.05%
0.04
+109.33%
-0.42
-72.02%
-0.24
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Net Income From Continuing Operation Net Minority Interest
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Net Income From Continuing And Discontinued Operation
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Net Income Continuous Operations
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Normalized Income
-38.61
-77.19%
-21.79
-13.82%
-19.14
-6.56%
-17.96
Net Income Common Stockholders
-37.92
-69.50%
-22.37
-14.35%
-19.56
-7.44%
-18.21
Otherunder Preferred Stock Dividend
0.00
-100.00%
0.62
0.00
—
Diluted EPS
-1.05
+13.93%
-1.22
+91.36%
-14.12
+62.75%
-37.91
Basic EPS
-1.05
+13.93%
-1.22
+91.36%
-14.12
+62.75%
-37.91
Basic Average Shares
36.21
+97.17%
18.36
+1225.17%
1.39
+188.30%
0.48
Diluted Average Shares
36.21
+97.17%
18.36
+1225.17%
1.39
+188.30%
0.48
Diluted NI Availto Com Stockholders
-37.92
-69.50%
-22.37
-14.35%
-19.56
-7.44%
-18.21
Total Other Finance Cost
-3.29
-263.50%
-0.90
-2839.39%
0.03
—
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total Assets
99.59
+90.75%
52.21
+1069.58%
4.46
-25.26%
5.97
Current Assets
98.52
+90.65%
51.67
+1285.73%
3.73
-22.63%
4.82
Cash Cash Equivalents And Short Term Investments
97.74
+92.16%
50.87
+1953.53%
2.48
-39.02%
4.06
Cash And Cash Equivalents
97.74
+92.16%
50.87
+1953.53%
2.48
-39.02%
4.06
Cash Equivalents
—
—
—
—
Cash Financial
97.74
+92.16%
50.87
+1953.53%
2.48
-39.02%
4.06
Receivables
0.03
-85.59%
0.23
+316.36%
0.06
+1733.33%
0.00
Accounts Receivable
0.03
-85.59%
0.23
+316.36%
0.06
+1733.33%
0.00
Prepaid Assets
—
—
—
0.74
Restricted Cash
0.11
+79.37%
0.06
+384.62%
0.01
-7.14%
0.01
Other Current Assets
0.63
+21.71%
0.52
-56.42%
1.18
+59.78%
0.74
Total Non Current Assets
1.07
+100.37%
0.54
-27.07%
0.73
-36.25%
1.15
Net PPE
0.99
+120.71%
0.45
-26.75%
0.61
-38.27%
0.99
Gross PPE
2.46
+32.81%
1.85
-4.04%
1.93
-11.22%
2.17
Accumulated Depreciation
-1.47
-4.70%
-1.40
-6.53%
-1.32
-11.51%
-1.18
Properties
0.00
0.00
0.00
0.00
Buildings And Improvements
0.86
+218.52%
0.27
-48.67%
0.53
-31.78%
0.77
Machinery Furniture Equipment
0.04
+15.79%
0.04
+0.00%
0.04
+2.70%
0.04
Other Properties
1.53
+0.79%
1.52
+13.25%
1.34
+0.00%
1.34
Leases
0.02
+0.00%
0.02
+0.00%
0.02
+0.00%
0.02
Non Current Prepaid Assets
0.08
-4.60%
0.09
+248.00%
0.03
+0.00%
0.03
Other Non Current Assets
—
0.06
-36.08%
0.10
-28.15%
0.14
Total Liabilities Net Minority Interest
2.30
-53.71%
4.96
+16.42%
4.26
+37.88%
3.09
Current Liabilities
1.80
-63.40%
4.92
+23.78%
3.98
+57.11%
2.53
Payables And Accrued Expenses
1.02
-75.46%
4.17
+28.91%
3.23
+71.86%
1.88
Payables
0.27
-82.00%
1.49
+23.16%
1.21
+145.23%
0.49
Accounts Payable
0.20
-85.12%
1.35
+18.51%
1.14
+170.14%
0.42
Other Payable
0.07
-51.45%
0.14
+100.00%
0.07
-2.82%
0.07
Current Accrued Expenses
0.75
-71.82%
2.68
+32.34%
2.02
+45.78%
1.39
Employee Benefits
0.00
-100.00%
0.04
—
—
Pensionand Other Post Retirement Benefit Plans Current
0.43
-10.32%
0.47
+0.64%
0.47
+18.00%
0.40
Current Debt And Capital Lease Obligation
0.35
+24.65%
0.28
+3.27%
0.28
+9.13%
0.25
Current Capital Lease Obligation
0.35
+24.65%
0.28
+3.27%
0.28
+9.13%
0.25
Total Non Current Liabilities Net Minority Interest
0.49
+1202.63%
0.04
-86.62%
0.28
-49.19%
0.56
Long Term Debt And Capital Lease Obligation
0.49
0.00
-100.00%
0.28
-49.19%
0.56
Long Term Capital Lease Obligation
0.49
0.00
-100.00%
0.28
-49.19%
0.56
Long Term Provisions
—
0.04
—
—
Stockholders Equity
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Common Stock Equity
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Capital Stock
0.00
+100.00%
0.00
0.00
0.00
Common Stock
0.00
+100.00%
0.00
0.00
0.00
Preferred Stock
0.00
0.00
—
—
Share Issued
26.25
+160.26%
10.09
+512.78%
1.65
+242.42%
0.48
Ordinary Shares Number
26.25
+160.26%
10.09
+512.78%
1.65
+242.42%
0.48
Additional Paid In Capital
326.31
+36.88%
238.40
+41.13%
168.92
+10.80%
152.45
Retained Earnings
-228.18
-19.93%
-190.26
-13.32%
-167.89
-13.19%
-148.33
Gains Losses Not Affecting Retained Earnings
-0.84
+5.94%
-0.89
-7.47%
-0.83
+33.33%
-1.25
Other Equity Adjustments
-0.84
+5.94%
-0.89
-7.47%
-0.83
+33.33%
-1.25
Total Equity Gross Minority Interest
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Total Capitalization
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Working Capital
96.72
+106.88%
46.75
+18875.10%
-0.25
-110.88%
2.29
Invested Capital
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Total Debt
0.85
+198.94%
0.28
-49.19%
0.56
-31.07%
0.81
Capital Lease Obligations
0.85
+198.94%
0.28
-49.19%
0.56
-31.07%
0.81
Net Tangible Assets
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Tangible Book Value
97.30
+105.92%
47.25
+23290.10%
0.20
-92.99%
2.88
Line Item Trend 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Operating Cash Flow
-23.59
-21.57%
-19.40
-7.72%
-18.01
-13.29%
-15.90
Cash Flow From Continuing Operating Activities
-23.59
-21.57%
-19.40
-7.72%
-18.01
-13.29%
-15.90
Net Income From Continuing Operations
-37.92
-74.32%
-21.75
-11.19%
-19.56
-7.44%
-18.21
Depreciation Amortization Depletion
0.40
+15.45%
0.34
-9.97%
0.38
-2.81%
0.39
Depreciation
0.40
+15.45%
0.34
-9.97%
0.38
-2.81%
0.39
Depreciation And Amortization
0.40
+15.45%
0.34
-9.97%
0.38
-2.81%
0.39
Other Non Cash Items
-0.76
—
—
—
Stock Based Compensation
17.43
+1999.52%
0.83
+83.63%
0.45
-48.05%
0.87
Unrealized Gain Loss On Investment Securities
0.00
-100.00%
0.00
-66.67%
0.00
-70.00%
0.01
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
-2.73
-332.45%
1.17
+64.43%
0.71
-31.15%
1.04
Change In Receivables
0.20
+211.93%
-0.18
-252.00%
-0.05
-5100.00%
0.00
Change In Prepaid Assets
-0.11
-117.21%
0.65
+255.80%
-0.41
-767.74%
0.06
Change In Payables And Accrued Expense
-2.46
-350.92%
0.98
-31.47%
1.43
+31.19%
1.09
Change In Accrued Expense
-0.08
-307.69%
0.04
-46.58%
0.07
—
Change In Payable
-2.38
-352.71%
0.94
-30.66%
1.36
+24.50%
1.09
Change In Other Working Capital
—
—
0.07
-8.75%
0.08
Change In Other Current Liabilities
-0.36
-29.45%
-0.28
-9.13%
-0.25
-28.57%
-0.20
Investing Cash Flow
-0.02
+89.94%
-0.18
-17800.00%
-0.00
+92.31%
-0.01
Cash Flow From Continuing Investing Activities
-0.02
+89.94%
-0.18
-17800.00%
-0.00
+92.31%
-0.01
Net PPE Purchase And Sale
-0.02
+89.94%
-0.18
-17800.00%
-0.00
+92.31%
-0.01
Purchase Of PPE
-0.02
+89.94%
-0.18
-17800.00%
-0.00
+92.31%
-0.01
Sale Of PPE
—
—
—
—
Capital Expenditure
-0.02
+89.94%
-0.18
-17800.00%
-0.00
+92.31%
-0.01
Financing Cash Flow
70.48
+3.61%
68.03
+324.78%
16.02
0.00
Cash Flow From Continuing Financing Activities
70.48
+3.61%
68.03
+324.78%
16.02
0.00
Net Common Stock Issuance
30.46
-57.03%
70.88
+296.35%
17.88
0.00
Proceeds From Stock Option Exercised
42.34
+1293.81%
3.04
—
—
Net Other Financing Charges
-2.32
+60.64%
-5.89
-215.25%
-1.87
—
Changes In Cash
46.88
-3.24%
48.45
+2524.77%
-2.00
+87.44%
-15.91
Effect Of Exchange Rate Changes
0.05
+712.50%
-0.01
-101.94%
0.41
+101.96%
0.20
Beginning Cash Position
50.93
+1945.34%
2.49
-38.91%
4.08
-79.40%
19.78
End Cash Position
97.86
+92.14%
50.93
+1945.34%
2.49
-38.91%
4.08
Free Cash Flow
-23.61
-20.55%
-19.58
-8.71%
-18.01
-13.20%
-15.91
Common Stock Issuance
30.46
-57.03%
70.88
+296.35%
17.88
0.00
Issuance Of Capital Stock
30.46
-57.03%
70.88
+296.35%
17.88
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category